About Ebenbuild
Ebenbuild is a company based in Munchen (Germany) founded in 2018 by Wolfgang Wall, Kei Muller, Jonas Biehler, and Karl-Robert Wichmann. Ebenbuild has raised $2.78 million across 3 funding rounds from investors including European Commission, Bayern Kapital and High-Tech Gründerfonds. Ebenbuild offers products and services including Clinical Decision Support and In Silico Trials. Ebenbuild operates in a competitive market with competitors including Unlearn, Verto Health, Virtonomy, Devellyn and VirtualMedSchool, among others.
- Headquarter Munchen, Germany
- Founders Wolfgang Wall, Kei Muller, Jonas Biehler, Karl-Robert Wichmann
-
Sectors
HealthcareTechnology
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Ebenbuild Gmbh
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$2.78 M (USD)
in 3 rounds
-
Latest Funding Round
$2.71 M (USD), Grant
Jul 02, 2025
-
Investors
European Commission
& 3 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Ebenbuild
Ebenbuild offers a comprehensive portfolio of products and services, including Clinical Decision Support and In Silico Trials.
Platform for informing efficient treatment decisions in hospitals.
Tool for optimizing drug delivery and tracking respiratory diseases.
People of Ebenbuild
Unlock access to complete
Funding Insights of Ebenbuild
Ebenbuild has successfully raised a total of $2.78M across 3 strategic funding rounds. The most recent funding activity was a Grant round of $2.71 million completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Ebenbuild
Ebenbuild has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include European Commission, Bayern Kapital and High-Tech Gründerfonds.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
High-tech industries are targeted for investments by Bayern Kapital.
|
Locked | Locked | Locked | |
|
Early-stage investments are made in high-tech startups by HTGF.
|
Locked | Locked | Locked | |
|
TechFounders is engaged in fostering partnerships between corporates and startups.
|
Locked | Locked | Locked |
Investor details for Ebenbuild
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Ebenbuild
Investment portfolio details for Ebenbuild
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Ebenbuild
Detailed financials for Ebenbuild
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ebenbuild Comparisons
Peer comparison for Ebenbuild
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Ebenbuild
Ebenbuild operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Unlearn, Verto Health, Virtonomy, Devellyn and VirtualMedSchool, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of AI-based clinical trial management software
|
|
| Locked | Locked | Locked |
A digital twin platform for population health management is offered.
|
|
| Locked | Locked | Locked |
Virtual patient simulations are provided for medical device development.
|
|
| Locked | Locked | Locked |
Indoor mapping and behavior pattern solutions for hospitals are provided.
|
|
| Locked | Locked | Locked |
Virtual simulations for medical training are provided online to professionals.
|
Detailed competitors of Ebenbuild
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ebenbuild
Complete news archive for Ebenbuild
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ebenbuild
Ebenbuild was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Ebenbuild is headquartered in Munchen, Germany. It is registered at Munchen, Bayern, Germany.
Kei Muller is the current CEO of Ebenbuild. They have also founded this company.
Ebenbuild is a funded company, having raised a total of $2.78M across 3 funding rounds to date.
Ebenbuild was founded in 2018 in Munich, Germany, and operates in the health technology sector. Precision therapy solutions based on digital twins are developed to optimize mechanical ventilation settings for patients with Acute Respiratory Distress Syndrome. Predictive computational models are utilized to offer individualized protective ventilation protocols, aiming to reduce ventilator-induced lung damage and support recovery outcomes.
Ebenbuild's top competitors include Unlearn, Verto Health and Virtonomy.
Ebenbuild offers Clinical Decision Support and In Silico Trials.
Ebenbuild has 4 investors. Key investors include European Commission, Bayern Kapital, High-Tech Gründerfonds, and TechFounders.